NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NRXS

Neuraxis Inc

Jul 03 • 01:50PM ET

2.58

Dollar change +0.17
Percentage change 7.05	%

Healthcare • Biotechnology • USA • AMEX

Peers: MDT BSX ABT SYK ISRG ZBH RMD EW ALGN BIO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	52.00%	Shs Outstand	7.22M	Perf Week	2.38%
Market Cap	22.57M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	8.95%	Shs Float	4.20M	Perf Month	-6.86%
Enterprise Value	20.95M	PEG	-	EPS next Q	-0.19	Inst Own	11.25%	Short Float	0.52%	Perf Quarter	20.00%
Income	-8.82M	P/S	7.70	EPS this Y	30.00%	Inst Trans	-24.68%	Short Ratio	0.01	Perf Half Y	7.50%
Sales	2.93M	P/B	73.23	EPS next Y	55.95%	ROA	-422.56%	Short Interest	0.02M	Perf YTD	9.79%
Book/sh	0.04	P/C	11.23	EPS next 5Y	45.90%	ROE	-2480.49%	52W High	6.20 -58.39%	Perf Year	-7.19%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	-25.70% -14.82%	ROIC	-1775.49%	52W Low	1.33 93.98%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-0.44% 8.61%	Gross Margin	85.86%	Volatility	4.17% 6.34%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.15	EPS Y/Y TTM	62.82%	Oper. Margin	-259.62%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.19	Sales Y/Y TTM	27.52%	Profit Margin	-300.66%	RSI (14)	52.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.21	EPS Q/Q	-3.15%	SMA20	3.84%	Beta	3.08	Target Price	6.25
Payout	-	Debt/Eq	1.50	Sales Q/Q	38.51%	SMA50	2.81%	Rel Volume	0.12	Prev Close	2.41
Employees	21	LT Debt/Eq	0.92	Earnings	May 12 BMO	SMA200	1.22%	Avg Volume	1.63M	Price	2.58
IPO	Aug 09, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	-37.50% 23.54%	Trades		Volume	131,874	Change	7.05%

Jun-27-25 04:53AM	The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technologies and NeurAxis (Zacks)
Jun-26-25 04:34PM	Top Stock Reports for Microsoft, NVIDIA & Bank of America (Zacks)
Jun-17-25 08:00AM	NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives (GlobeNewswire)
Jun-10-25 08:00AM	NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS (GlobeNewswire) -8.65%
May-27-25 08:00AM	NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 (GlobeNewswire)
01:03PM	Loading…
May-22-25 01:03PM	NeurAxis Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) -5.31%
May-21-25 07:00AM	NeurAxis Announces $5.0 Million Registered Direct Offering (GlobeNewswire) -19.80%
May-20-25 08:00AM	NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms (GlobeNewswire) +75.77%
May-15-25 12:06PM	NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones (Zacks)
May-12-25 08:15AM	NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues (GlobeNewswire) +16.00%
May-05-25 09:00AM	NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 (GlobeNewswire) -11.64%
May-01-25 04:49AM	The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis (Zacks)
Apr-30-25 05:02PM	Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems (Zacks) +5.86%
Apr-15-25 09:00AM	NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 (GlobeNewswire)
Mar-24-25 11:20AM	NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth (Zacks) -6.06%
04:18PM	Loading…
Mar-20-25 04:18PM	NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:15AM	NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues (GlobeNewswire)
Mar-12-25 09:00AM	NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 (GlobeNewswire)
Jan-21-25 01:45PM	UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States (GlobeNewswire)
09:00AM	NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States (GlobeNewswire)
Jan-13-25 09:00AM	NeurAxis Inc. Issues Letter to Shareholders (GlobeNewswire)
Jan-08-25 09:00AM	NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year (GlobeNewswire)
Jan-06-25 09:00AM	NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire) +11.57%
Dec-10-24 09:00AM	NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation (GlobeNewswire) -7.48%
Nov-12-24 08:10AM	NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues (GlobeNewswire) +26.40%
Nov-05-24 09:00AM	NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 (GlobeNewswire)
Nov-04-24 09:00AM	NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market (GlobeNewswire)
Oct-29-24 09:00AM	NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 (GlobeNewswire)
Oct-22-24 09:00AM	NeurAxis Announces New CPT Category I Code for Percutaneous Electrical Nerve Field Stimulation (GlobeNewswire) +5.07%
Sep-19-24 09:00AM	NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
09:00AM	Loading…
Aug-27-24 09:00AM	NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 (GlobeNewswire)
Aug-13-24 09:00AM	NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 (GlobeNewswire)
Aug-09-24 08:00AM	NeurAxis Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.12%
Aug-05-24 09:00AM	NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 (GlobeNewswire) -17.61%
Jun-07-24 09:00AM	NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure (GlobeNewswire)
May-22-24 08:00AM	NeurAxis Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-21-24 09:00AM	NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (GlobeNewswire)
May-16-24 09:00AM	NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida (GlobeNewswire) +11.96%
May-15-24 04:30PM	NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024 (GlobeNewswire)
Apr-23-24 09:00AM	NeurAxis Announces New Medical Policy Coverage in North Dakota (GlobeNewswire) -11.18%
Apr-12-24 08:44AM	NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-09-24 04:05PM	NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 04:15PM	NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024 (GlobeNewswire)
Mar-27-24 09:00AM	NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry (GlobeNewswire)
Mar-11-24 09:00AM	NeurAxis Announces Highmark BCBS Policy Coverage (GlobeNewswire)
Mar-04-24 09:00AM	NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage (GlobeNewswire) +8.82%
Feb-27-24 11:00AM	NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference (GlobeNewswire)
Jan-31-24 09:00AM	NeurAxis Appoints Timothy Henrichs as Chief Financial Officer (GlobeNewswire)
Dec-20-23 09:00AM	NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer (GlobeNewswire)
Nov-20-23 05:30PM	NeurAxis Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-15-23 09:00AM	NeurAxis Announces CareFirst BCBS Policy Coverage (GlobeNewswire) +14.17%
Nov-14-23 09:00AM	NeurAxis Secures $3 Million Financing (GlobeNewswire)
Nov-08-23 09:00AM	NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device (GlobeNewswire)
Sep-26-23 09:00AM	NeurAxis Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders (GlobeNewswire)
Sep-21-23 08:00AM	NeurAxis Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Sep-13-23 09:00AM	NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) +7.87%
Sep-12-23 10:15AM	EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome (Benzinga) -16.92%
09:00AM	NeurAxis Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS (GlobeNewswire)
Aug-29-23 09:00AM	NeurAxis Highlights Pediatric Post-Concussion Clinical Study (GlobeNewswire)
Aug-24-23 09:00AM	NeurAxis Highlights Strength of its Board of Directors (GlobeNewswire) -10.15%
Aug-22-23 09:00AM	NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome (GlobeNewswire) +16.50%
Aug-17-23 09:02AM	NeurAxis Announces Over $8 Million in IB-Stim Revenue (GlobeNewswire)
Aug-15-23 09:00AM	NeurAxis Announces Positive University of Michigan IB-Stim Cost Effectiveness Study at ANMS 2023 (GlobeNewswire)
Aug-11-23 09:30AM	Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc. (ACCESSWIRE)
Aug-10-23 09:00AM	NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin (GlobeNewswire)
09:00AM	Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing (GlobeNewswire)
Aug-09-23 10:00AM	NeurAxis Announces Pricing of Initial Public Offering (GlobeNewswire)

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. Its product, IB-Stim, is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hannasch Brian	10% Owner	Jul 01 '25	Buy	2.25	355,556	800,001	1,131,522	Jul 03 11:24 AM
Hannasch Brian	10% Owner	Apr 21 '25	Buy	1.73	18,065	31,251	775,966	Apr 23 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXS

Neuraxis Inc

Upgrade your FINVIZ experience